Drug Profile
Research programme: inflammatory bowel diseases therapeutics - Celgene/Inception IBD
Latest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Inception IBD
- Developer Celgene Corporation; Inception IBD
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 28 Jul 2019 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA
- 10 Dec 2015 Inception IBD and Celgene enter into a collaboration to discover and develop Inflammatory bowel disease therapeutics for Inflammatory bowel diseases